Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Stem cell therapies for Alzheimer's disease

is it time?

Wang, Sheng-Mina; Lee, Chang-Ukb; Lim, Hyun Kooka

Current Opinion in Psychiatry: March 2019 - Volume 32 - Issue 2 - p 105–116
doi: 10.1097/YCO.0000000000000478
NEUROCOGNITIVE DISORDERS: Edited by Perminder S. Sachdev and Michael Valenzuela

Purpose of review Stem cell therapy has the potential to modify the disease of Alzheimer's disease. This article aims to describe the mechanisms of action, preclinical animal studies, human clinical trials, and challenges for the future direction of stem cell therapy for Alzheimer's disease.

Recent findings Stem cells of diverse origins (embryonic, placental or umbilical cord blood, and induced pluripotent stem cells) and cell types (neural and mesenchymal stem cells) are widely studied in both animals and humans.

Summary In terms of mechanism of actions, recent research focused on the interplay between amyloid-beta Aβ (and tau), neurons, and glia. Stem cells can induce direct regeneration of neurons and synapses. They can also prevent activation of pro-inflammatory microglia, promote activation of anti-inflammatory microglia, inhibit astrogliosis, and promote nonreactive astrocytes. These effects in return may increase amyloid-beta (Aβ) degradation, decrease the risk of the Aβ cascade, repair injured neurons, and enhance synaptogenesis. Two completed and nine ongoing clinical trials using diverse stem cells and administration methods (intravenous, subcutaneous, and intra-cranial) were found for the treatment of Alzheimer's disease. Although stem cell therapy shows great potential to become a prospective treatment for Alzheimer's disease in the future, these studies are still in their early stages and more studies showing safety and efficacy are needed.

aDepartment of Psychiatry, Yeouido St. Mary's Hospital

bDepartment of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence to Hyun Kook Lim, MD, PhD, Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, Republic of Korea. Tel: +82 2 3779 1048; fax: +82 2 780 6577; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.